PMDA drug package insert
カルボシステイン錠250mg「TCK」
PMDA Prescription drug · 辰巳化学株式会社 · package insert Oct 20, 2023
Key facts
| Brand names | カルボシステイン錠250mg「TCK」, カルボシステイン錠500mg「TCK」 |
|---|---|
| Nonproprietary names | Ｌ－カルボシステイン |
| Companies | 製造販売元／辰巳化学株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 気道粘液調整・粘膜正常化剤 |
| Therapeutic category codes | 872233 |
| YJ codes | 2233002F1336, 2233002F2154 |
| Approval numbers | 23000AMX00104000, 23000AMX00105000 |
| Package insert edition | 第1版 |
| Package insert date | Oct 20, 2023 |
| PMDA document key | 400278_2233002F1336_1 |
| PMDA company code | 400278 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: